It's a little bit premature to be declaring victory until we've had a large enough number of clinical trials and enough people treated for long periods of time to understand the risk-to-benefit ratio better.
Those having a heart attack will have a far lower risk of having a second heart attack, a stroke, or their death rate is lowered almost a quarter. Aspirin has the best benefit to risk ratio and benefit to cost ratio of any therapy of acute heart attacks.